<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590445</url>
  </required_header>
  <id_info>
    <org_study_id>OCD pilot</org_study_id>
    <nct_id>NCT02590445</nct_id>
  </id_info>
  <brief_title>Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder</brief_title>
  <official_title>Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Refractory obsessive-compulsive disorder (OCD) is a disabling condition. Deep brain
      stimulation (DBS) of ventral capsule/ventral striatum(VC/VS) is potentially the most
      effective treatment for refractory OCD. However, the affecting area of traditional electrodes
      is limited and not specific to VC/VS. The investigators designed a novel electrode, 2 mental
      contacts(3mm contact-2mm space-3 mm contact) could be implanted in ventral striatum and the
      other upper 2 contacts(4mm space-3mm contact-4mm space-3mm contact)that can be implanted in
      ventral capsule simultaneously, which the investigators believe will be more effective due to
      better compatibly with anatomical features of target area. This trial is to evaluate the
      effectiveness and safety of this approach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 5 months, 6 months, 8 months, 12 months, 18 month, 24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 5 months, 6 months, 8 months, 12 months, 18 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 5 months, 6 months, 8 months, 12 months, 18 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17 Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 5 months, 6 months, 8 months, 12 months, 18 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional magnetic resonance imaging (fMRI) images</measure>
    <time_frame>Baseline (preoperative)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Global assessment of function</measure>
    <time_frame>Baseline (preoperative), 8 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability: WHO disability assessment 2.0</measure>
    <time_frame>Baseline (preoperative), 8 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurobehavior Task (Decision making task, such as Model task, IGT)</measure>
    <time_frame>Baseline (preoperative), 8 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurobehavior Task (Working memory task, such as N-back)</measure>
    <time_frame>Baseline (preoperative), 8 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability: Sheehan Disability Scale</measure>
    <time_frame>Baseline (preoperative), 8 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Obsessional beliefs questionnaire (OBQ-44) Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 5 months, 6 months, 8 months, 12 months, 18 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adult Temperament Questionnaire (ATQ-77) Score</measure>
    <time_frame>Baseline (preoperative), 8 months, 12month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Temperament and Character Inventory Revised (TRI-R) Score</measure>
    <time_frame>Baseline (preoperative), 8 months, 12month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral glucose metabolism measured by PET-CT images</measure>
    <time_frame>Baseline (preoperative), 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stimulator on followed by off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Stimulator off followed by on</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>deep brain stimulation system</intervention_name>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 65 years.

          2. A primary diagnosis of OCD, defined according to the criteria of the Diagnostic and
             Statistical Manual of Mental Disorders, fifth edition (DSM-V).

          3. Chronic: at least a 3-year history of OCD symptoms with psychosocial dysfunction

          4. Severity: a score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) of more than
             25 or one subscale score of more than 15 ; a score for severity of illness on the
             Clinical Global Impression (CGI) scale of more than 4.

          5. Disability: a score on the Global Assessment Functioning (GAF) scale of less than 45
             or a score on Sheehan Disability Scale more than 24.

          6. Refractory: a lack of response to drug therapy after adequate administration, defined
             as more than two types of serotonin reuptake inhibitors at the maximum tolerated dose
             for more than 12 weeks. Adequate behavior therapy, defined as more than 20 sessions
             psychotherapy with experienced therapist.

          7. OCD medication regimen is stable for at least 4 weeks before enrollment.

        Exclusion Criteria:

          1. Schizophrenic disorder; bipolar disorder; substance abuse or dependence (except for
             dependence on nicotine), as assessed with the use of the Mini-International
             Neuropsychiatric Interview (MINI 6.0.0).

          2. Cluster A or B personality disorder according to DSM-IV-TR criteria, as assessed with
             the use of the Structured Clinical Interview II.

          3. A current severe major depressive episode, determined according to DSM-V criteria (as
             assessed with the use of the MINI 6.0.0) and defined by the Hamilton Depression Rating
             Scale-17 (HAMD) score of more than 20 and a risk of suicide.

          4. Abnormal cognitive status (measured by MoCA), abnormal findings on functional magnetic
             resonance imaging (MRI) of the brain, or contraindications to surgery or anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bomin Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chencheng Zhang, MD</last_name>
    <phone>+8618217122884</phone>
    <email>i@cczhang.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chencheng Zhang, MD</last_name>
    <phone>+8618217122884</phone>
    <email>i@cczhang.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chencheng Zhang, MD</last_name>
      <phone>+86 18217122884</phone>
      <email>i@cczhang.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010 Mar 15;67(6):535-42. doi: 10.1016/j.biopsych.2009.11.028. Epub 2010 Feb 8.</citation>
    <PMID>20116047</PMID>
  </reference>
  <reference>
    <citation>Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.</citation>
    <PMID>19005196</PMID>
  </reference>
  <reference>
    <citation>Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2010 Oct;67(10):1061-8. doi: 10.1001/archgenpsychiatry.2010.122.</citation>
    <PMID>20921122</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Director of functional neurosurgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

